CClinicalTrials.gg
RecruitingNCT07109570SERA-EffortUpdated Nov 26, 2025

Surface Electrical Myography, Oxygen Consumption, Effort, and Weaning in the Mechanically Ventilated Patient in the Intensive Care Unit

An observational study in Critical Illness, Intensive Care Units (ICUs) and Weaning Failure, sponsored by Leiden University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Leiden University Medical Center · Observational

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to measure effort using esophageal pressure measurements, oxygen consumption and diaphragm activity in mechanically ventilated Intensive Care Unit patients during a Spontaneous Breathing Trial. The main question aims to answer whether the sEMG signal derived from the SERA device, effort parameters and oxygen consumption have an association with weaning failure.

Participants will be measured while performing a spontaneous breathing trial.

Read the detailed description

Rationale: In patients mechanically ventilated for more than 72 hours weaning from the ventilator and successful extubation can be problematic. The spontaneous breathing trial (SBT) is a tool to predict successful extubation. However re-intubation withing 48 hours occurs in 15-20% of the patients after a successful SBT. The key parameter of the SBT is the rapid shallow breathing index (RSBI). Since the rate of extubation failure is still high the search for a better parameter than the RSBI is warranted.

Recently measurement of the surface electromyography of the respiratory muscles has become available with the Surface Electromyography Respiratory Assist (SERA), which has been developed by Demcon-Macawi. The device is currently investigated in neonates in search of an apnea detection algorithm (protocol ID NL83937.000.23). The device gives an estimate of the magnitude of the electric activity of the diaphragm which has a good correlation with the force the diaphragm generates. It is known that the diaphragm is the key respiratory muscle and that dysfunction of the diaphragm has a strong association with weaning failure. We think that this signal could be of great value in detecting weaning and extubation failure therefore we want to investigate if the sEMG signal derived from the SERA device has an association with weaning failure, defined as an unsuccessful SBT, or extubation failure, defined as the need for re-intubation for respiratory reasons within 48 hours after a successful SBT and subsequent extubation.

Objective: Primary objective is to investigate if the sEMG signal derived from the SERA device has an association with weaning failure, defined as an unsuccessful SBT, or extubation failure, defined as the need for re-intubation for respiratory reasons within 48 hours after a successful SBT and subsequent extubation.

Secondary objectives are to investigate if the sEMG signal has an association with other measurements of effort (pressure time product (PTP), Work of breathing (WOB), Transpulmonary pressure swings, oesophageal pressure swings, and oxygen consumption).

Study design: A single center prospective cohort feasibility/pilot study performed on patients undergoing a spontaneous breathing trial. Measurements will commence 10 minutes before the planned SBT, will continue during the SBT until 10 minutes after the termination of the SBT. Measurement data will be derived from the SERA, the mechanical ventilator (Hamilton C6), and the Masimo ISA OR+. The SBT will done according to the ruling protocol in the LUMC.

Intervention: None Main study parameters/endpoints: Magnitude of the electric signal (base level, or tonic level, maximum level, AUC of the electric signal during contraction in inspiration and expiration, differences between maximum and tonic levels), VO2, PTP, WOB, RSBI, diaphragmatic pressure swing.

Nature and extent of the burden and risks associated with participation, benefit, and group relatedness: The collection of data will not affect the standard of care. Therefore, the patient's risk is negligible and the burden is minimal.

02

Conditions studied

  • Critical Illness
  • Intensive Care Units (ICUs)
  • Weaning Failure
  • Mechanical Ventilation
  • Spontaneous Breathing Trial
  • Diaphragm Electrical Activity
  • Oxygen Consumption

Browse trials for

03

In context

Critical Illness

1,881 studies on the registry are indexed under Critical Illness; 462 are open to participants now.

This study's planned enrollment of 60 is below the median of 130 across 867 observational studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Leiden University Medical Center is the lead sponsor of 326 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The intended population consists of adults who are mechanically ventilated in the ICU and meet the criteria for a regular spontaneous breathing trial according to the ruling LUMC protocol.

Inclusion criteria

  • 18 years of age or older
  • Esophageal catheter in situ (standard of care)
  • Eligible for an SBT in the near future according to the LUMC SBT protocol currently valid

Exclusion criteria

Exclusion Criteria:

  • Severe cardiac failure NYHA class IV without mechanical support (LVAD or Impella)
  • COPD Gold IV
  • Pregnancy
  • Patients with ECMO
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
2 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Extubation failure

    Extubation failure is defined by the need for reintubation or death.

    Time frame: 48 hours after extubation

  2. sEMG differences during SBT

    The AUC of the voltage signal, the phasic level (difference between tonic level and maximum level) and the tonic level (base level).

    Time frame: 10 minutes before switch from support to no support ventilation, the whole duration of the SBT, and the 10 minutes after the SBT when there is again support.

Secondary outcomes

  1. Differences of oxygen consumption during SBT

    The values of oxygen consumption (in milliliter/minute) and the differences between start, during, and end of the SBT.

    Time frame: 10 minutes before, through SBT (average of 30 minutes) and 10 minutes after SBT

  2. Differences of esophageal pressure swings measured with an esophageal catheter during SBT

    The values of pressure swings (in cmH2O), measured with an esophageal catheter, and the differences between start, during, and end of the SBT.

    Time frame: 10 minutes before, through SBT (average of 30 minutes) and 10 minutes after SBT

  3. Differences of work of breathing measured with an esophageal catheter during SBT

    The values of work of breathing (in Joules/liter), measured with an esophageal catheter, and the differences between start, during, and end of the SBT.

    Time frame: 10 minutes before, through SBT (average of 30 minutes) and 10 minutes after SBT

  4. Differences of pressure-time product measured with an esophageal catheter during SBT

    The values of pressure-time product (in cmH2O/seconds), measured with an esophageal catheter, and the differences between start, during, and end of the SBT.

    Time frame: 10 minutes before, through SBT (average of 30 minutes) and 10 minutes after SBT

  5. Differences of rapid shallow breathing index during SBT

    The values of rapid shallow breathing index (breaths/minute/liter) and the differences between start, during, and end of the SBT.

    Time frame: 10 minutes before, through SBT (average of 30 minutes) and 10 minutes after SBT

07

Study locations

1 of 1 sites recruiting
  • Leiden University Medical Centre
    Leiden, 2300 ZA, Netherlands
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07109570
Lead sponsor
Leiden University Medical Center
Collaborators
Demcon-Macawi
Responsible party
Abraham Schoe, MD, PhD. (MD, PhD, Leiden University Medical Center) — Principal investigator
First posted
Aug 7, 2025
Start date
Jul 8, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 26, 2025

Study contacts

Abraham Schoe, MD, PhD
Contact
a.schoe@lumc.nl
+31715265018
Florence E Smits, MSc
Contact
f.e.smits@lumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion